Sefaxersen sodium
Based on 1 Customer Validation
Sefaxersen sodium is a specific antisense oligonucleotide (ASO) targeting complement factor B (CFB). Sefaxersen sodium effectively reduces circulating levels of CFB, and can be used for geographic atrophy (GA) research.
For research use only. We do not sell to patients.
- Purity: 99.46%
- CAS No.: 2272983-11-4
- Molecular Weight:8678.96 (free acid)
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biological Activity
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2272983-11-4
-
Appearance Solid
-
Molecular Weight 8678.96 (free acid)
-
Color Off-white to light yellow
-
SMILES
[Sefaxersen sodium]
-
Synonyms
IONIS-FB-LRx sodium; RG6299 sodium; ISIS 696844 sodium
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H2O : 100 mg/mL (Need ultrasonic)
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2242 KB)
References
[1]. Dreismann AK, et al. Gene targeting as a therapeutic avenue in diseases mediated by the complement alternative pathway. Immunol Rev. 2022 Nov 12. [Content Brief]
[2]. Mahmoudzadeh R, et al. Emerging treatments for geographic atrophy in age-related macular degeneration. Curr Opin Ophthalmol. 2021 May 1;32(3):294-300. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)